Mannucci P M, Cugno M, Bottasso B, Marongiu F, Maniezzo M, Vaglini M, Cascinelli N
A. Bianchi Bonomi Hemophilia and Thrombosis Center, University of Milan, Italy.
Eur J Cancer. 1990 Feb;26(2):83-7. doi: 10.1016/0277-5379(90)90287-4.
An array of fibrinolysis tests was applied to the plasmas of 125 untreated patients with breast carcinoma and malignant melanoma, localized or spread to regional lymph nodes with no detectable distant metastases, to see whether or not there may be changes related to the type or to the stage of malignancy. Breast carcinoma (a mucin secreting tumor) and melanoma (a neuroectodermal tumor) were chosen as examples of tumors that can be accurately staged for localization or spread. Forty healthy subjects matched for age served as controls. The most marked differences between malignant tumors and controls were elevated plasma levels of tissue plasminogen activator antigen (P less than 0.005), plasminogen activator inhibitor (P less than 0.01), cross-linked fibrin degradation products (P less than 0.001), fragment B beta 15-42 (P less than 0.001) and histidine-rich glycoprotein (P less than 0.005). For no fibrinolysis test were results significantly different between patients with localized and spread tumors. Our data indicate that in these tumors fibrinolytic alterations are an early phenomenon unrelated to spreading.
对125例未经治疗的乳腺癌和恶性黑色素瘤患者的血浆进行了一系列纤维蛋白溶解试验。这些患者的肿瘤局限或已扩散至区域淋巴结，但未检测到远处转移，目的是观察是否存在与恶性肿瘤类型或分期相关的变化。乳腺癌（一种分泌粘蛋白的肿瘤）和黑色素瘤（一种神经外胚层肿瘤）被选作能够准确分期以确定其定位或扩散情况的肿瘤实例。40名年龄匹配的健康受试者作为对照。恶性肿瘤患者与对照组之间最显著的差异在于血浆组织纤溶酶原激活物抗原水平升高（P<0.005）、纤溶酶原激活物抑制剂水平升高（P<0.01）、交联纤维蛋白降解产物水平升高（P<0.001）、Bβ15 - 42片段水平升高（P<0.001）以及富含组氨酸糖蛋白水平升高（P<0.005）。对于所有纤维蛋白溶解试验，局限性肿瘤患者和扩散性肿瘤患者的结果均无显著差异。我们的数据表明，在这些肿瘤中，纤维蛋白溶解改变是一种与扩散无关的早期现象。
